follows: chemotherapy; anti-EGFR therapy ± chemotherapy; anti-VEGF therapy ± chemotherapy; HER2-directed therapy; tipiracil + trifluridine; regorafenib; and non–NCCN-recommended therapies (which included paclitaxel, carboplatin, cisplatin, gemcitabine
Search Results
John H. Strickler, Ling-I Hsu, Phoebe Wright, Michael Stecher, Muriel F. Siadak, Maria Corinna Palanca-Wessels, Junhua Yu, Nicole Zhang, Carin R. Espenschied, Kathryn Lang, and Tanios S. Bekaii-Saab
Harold J. Burstein
provide confirmatory evidence supporting the original ECOG 2100 study that had led to accelerated approval of bevacizumab in combination with paclitaxel for advanced breast cancer. The FDA will decide in September whether to withdraw the label for the
Presented by: William J. Gradishar
are given earlier in the course of metastatic disease rather than later, he added. Less frequently, microsatellite instability–high (MSI-H) status can also be exploited with the anti–PD-L1 agent atezolizumab + nab-paclitaxel. The rate NTRK fusions
Zhi Ven Fong and Cristina R. Ferrone
horizon for patients with metastatic PDAC significantly changed with the multiagent chemotherapy regimens fluorouracil/folinic acid/irinotecan/oxaliplatin (FOLFIRINOX) 4 and gemcitabine/nab-paclitaxel, 5 respectively. Median survival for patients with
A. Dimitrios Colevas
SCCHN. 9 - 15 The most robustly studied agents are cisplatin, carboplatin, methotrexate, 5-fluorouracil (5-FU), ifosfamide, paclitaxel, and docetaxel ( Table 1 ). Response rates typically range from 10% to 30%, with some outlier reports of higher
Michael Xiang, A. Dimitrios Colevas, F. Christopher Holsinger, Quynh-Thu X. Le, and Beth M. Beadle
combination chemotherapy ( Figure 2A ), which was predominantly with paclitaxel. By contrast, 86% of patients in the cisplatin cohort received cisplatin monotherapy ( Figure 2B ). H&N CSM was higher for single-agent carboplatin than for multiagent chemotherapy
Aatur D. Singhi, Siraj M. Ali, Jill Lacy, Andrew Hendifar, Khanh Nguyen, Jamie Koo, Jon H. Chung, Joel Greenbowe, Jeffrey S. Ross, Marina N. Nikiforova, Herbert J. Zeh, Inderpal S. Sarkaria, Anil Dasyam, and Nathan Bahary
regimens, including gemcitabine plus nab-paclitaxel and FOLFIRINOX (5-fluorouracil, folinic acid, oxaliplatin, and irinotecan), have limited efficacy, with an incremental survival benefit of only a few months in unselected patients. However, significant
Héctor G. van den Boorn, Willemieke P.M. Dijksterhuis, Lydia G.M. van der Geest, Judith de Vos-Geelen, Marc G. Besselink, Johanna W. Wilmink, Martijn G.H. van Oijen, and Hanneke W.M. van Laarhoven
: Fluoropyrimidine, platinum, and irinotecan (eg, FOLFIRINOX [5-FU/leucovorin/oxaliplatin/irinotecan]) Regimens with gemcitabine and nab-paclitaxel Gemcitabine monotherapy Other regimens Predictor Preselection Predictors were selected based on
Medhavi Gupta, Christopher Sherrow, Maghan E. Krone, Edik M. Blais, Michael J. Pishvaian, Emanuel F. Petricoin III, Lynn M. Matrisian, Patricia DeArbeloa, Gary Gregory, Alyson Brown, Olivia Zalewski, Gillian Prinzing, Charles Roche, Kazunori Kanehira, Sarbajit Mukherjee, Renuka Iyer, and Christos Fountzilas
surveillance CT 6 months later showed disease progression with enlarging lymph nodes. Gemcitabine was reintroduced at a lower dose of 800 mg/m 2 on days 1 and 8 of a 21-day cycle. Nab-paclitaxel was added to gemcitabine from cycle 6 onward because of further
Eva Battaglini, David Goldstein, Peter Grimison, Susan McCullough, Phil Mendoza-Jones, and Susanna B. Park
treatments for these cancers: taxanes (docetaxel: n=322 [32.7%]; paclitaxel: n=312 [31.6%]), platinum-based chemotherapies (oxaliplatin: n=123 [12.5%]; cisplatin: n=53 [5.4%]), thalidomide (n=87; 8.8%), and bortezomib (n=82; 8.3%). One-quarter of respondents